Our mission is to devise new imaging approaches that will improve early cancer diagnosis.

We are an international team combining physicists, engineers, chemists, and molecular biologists who work at the clinical interface. Our imaging innovations arise primarily from low cost optics and photonics technologies, applied both in cancer models and in patients. We are particularly interested in developing methods to interrogate cancer metabolism and the tumour microenvironment. Importantly, we place emphasis on biological validation of the imaging biomarkers that we measure, connecting our non-invasive imaging signatures with the molecular processes that generate them.

We achieve developments in this area through a combination of: modelling, to understand the interactions between light and tissue; and innovative instrument design, integrating new technologies to enable spectral imaging. By applying such developments to preclinical disease models and ultimately in patients, we aim to better understand cancer progression, from early development through to treatment resistance.